|Dr. Guy Chamberland M.Sc., Master Herbal, Ph.D.||Co-Founder, CEO, Chief Regulatory Officer & Director||N/A||N/A||1962|
|Mr. AndrÃ© Rancourt B.Sc.||Co-Founder||N/A||N/A||N/A|
|Mr. Jean-Francois Boily C.A., CPA||Chief Financial Officer||N/A||N/A||N/A|
|Dr. Graham Wood||Chief Operating Officer||N/A||N/A||N/A|
|Dr. Melanie Edna Mary Kelly||Chief Scientific Officer||N/A||N/A||N/A|
|Jennifer McCaughey||VP of Investor Relations||N/A||N/A||N/A|
|Mr. Steeve NÃ©ron||Chief Commercial Officer||N/A||N/A||N/A|
|Ms. Dania Scott B.Sc.||Sr. VP of Commercial Strategy||N/A||N/A||N/A|
|Mr. Richard Giguere||Chief Exec. Officer of Tetra Natural Health Inc.||N/A||N/A||N/A|
|Randy Ringuette||Project Director & Member of Advisory Board||N/A||N/A||N/A|
Tetra Bio-Pharma Inc., a development stage biopharmaceutical company, engages development of cannabinoid-based medicines. It develops drugs for chronic pain, which includes SERENITY for cancer cachexia, which is clinical phase 2; REBORN, drug for breakthrough pain, which is in clinical phase 2; and PLENITUDE for advanced cancer pain, which is clinical phase 1. The company also develops PPP003, drug for painful dry eye and uveitis pain, which is in clinical phase 1; and HCC011 for hepatocellular carcinoma.It has collaboration agreements with Aphria Inc.; IntelGenx Corp.; Panag Pharma Inc.; the University of New Brunswick; and Ovensa Inc. The company also has a co-development partnership with Storz & Bickel for the treatment of fibromyalgia. The company was formerly known as GrowPros Cannabis Ventures Inc. and changed its name to Tetra Bio-Pharma Inc. in September 2016. Tetra Bio-Pharma Inc. is headquartered in Orleans, Canada.
Tetra Bio-Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.